Forest Laboratories, Inc. Files Lawsuits against Several Companies for Infringement of BYSTOLIC® Patent
March 14 2012 - 11:49AM
Business Wire
Forest Laboratories, Inc. (NYSE: FRX) and
Forest Laboratories Holdings, Ltd. (collectively, “Forest”)
announced that Forest and Janssen Pharmaceutica NV have jointly
filed a lawsuit in the U.S. District Court for the District of
Delaware against several companies for infringement of U.S. Patent
No. 6,545,040 (“the ‘040 patent”), relating to Forest’s BYSTOLIC®
product. Forest licenses the ‘040 patent from Janssen. The ‘040
patent expires in December 2021, including patent term
extension.
The defendants named in the lawsuit include
Amerigen Pharmaceuticals, Inc., Glenmark Generics, Inc., Hetero USA
Inc., Torrent Pharmaceuticals Ltd., Watson Laboratories, Inc., and
related companies and subsidiaries thereof. Janssen and Forest also
filed a lawsuit in the U.S. District Court for the Northern
District of Illinois against Alkem Laboratories Limited and
Indchemie Health Specialties Pvt. Ltd for infringement of the ‘040
patent.
Janssen and Forest received notification from
these companies that they had filed Abbreviated New Drug
Applications with Paragraph IV certifications seeking approval to
market generic versions of BYSTOLIC before the expiration of the
‘040 patent. The aforementioned lawsuits were commenced before the
expiration of forty-five days from the date of receipt of each
notification letter.
About Forest
Laboratories
Forest Laboratories’ (NYSE: FRX) longstanding
global partnerships and track record developing and marketing
pharmaceutical products in the United States have yielded its
well-established central nervous system and cardiovascular
franchises and innovations in anti-infective and respiratory
medicine. The Company’s pipeline, the most robust in its history,
includes product candidates in all stages of development across a
wide range of therapeutic areas. The Company is headquartered in
New York, NY. To learn more, visit www.FRX.com.
Except for the historical information contained
herein, this release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
These statements involve a number of risks and uncertainties,
including the difficulty of predicting FDA approvals, the
acceptance and demand for new pharmaceutical products, the impact
of competitive products and pricing, the timely development and
launch of new products, and the risk factors listed from time to
time in Forest Laboratories’ Annual Reports on Form 10-K, Quarterly
Reports on Form 10-Q, and any subsequent SEC filings.
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jul 2023 to Jul 2024